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Abstract
The poor solubility of cisplatin (CDDP) often presents a major obstacle in the formulation of
CDDP in nanoparticles (NPs) by traditional methods. We have developed a novel method for
synthesizing CDDP NPs taking advantage of its poor solubility. By mixing two reverse
microemulsions containing KCl and a highly soluble precursor of CDDP, cis-
diaminedihydroplatinum (II), we have successfully formulated CDDP NPs with a controllable size
(in the range of 12–75 nm) and high drug loading capacity (approximately 80 wt%). The
formulation was done in two steps. The pure CDDP NPs were first stabilized for dispersion in an
organic solvent by coating with 1, 2-dioleoyl-sn-glycero-3-phosphate (DOPA). Both x-ray
photoelectron spectroscopy and 1H NMR data confirmed that the major ingredient of the DOPA-
coated NPs was CDDP. After purification, additional lipids were added to stabilize the NPs for
dispersion in an aqueous solution. The final NPs contain a lipid bilayer coating and are named
Lipid-Pt-Cl (LPC) NPs, which showed significant antitumor activity both in vitro and in vivo.
Thus, CDDP precipitate serves as the major material for assembling the novel NPs. This unique
method of nanoparticle synthesis may be applicable in formulating other insoluble drugs.
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1. Introduction
Cisplatin (CDDP) is a chemotherapy drug commonly used in the clinical setting. In clinics,
maximum tolerated dose (MTD) of CDDP is significantly limited by nephrotoxicity [1, 2].
To improve patient care, carboplatin and oxaliplatin are administered, while altering the
chloride leaving groups of CDDP with 1,2-diaminocyclohexane or an oxalate ligand
compromises outcome [1].
In order to maintain the efficacy and reduce the nephrotoxicity of cisplatin, nanoparticulate
CDDP formulations are very promising. Nanoparticulate CDDP formulations have been
achieved through chelating CDDP with polymers and NPs [3–5], loading of a pro-drug in
the poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) or encapsulating CDDP into
liposomes [3, 6–13]. For example, CDDP was loaded into PLGA NPs by exploiting double
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emulsion technique, while the encapsulation and loading efficacy were low and burst release
was often observed [14]. Dhar et al utilized a prodrug strategy, i.e., modified the
hydrophobicity of CDDP, and therefore improved the encapsulation of CDDP into PLGA
NPs [13, 15, 16]. Kataoka et al alternatively chelated CDDP positively charged platinum
species to carboxylate-rich copolymers with a drug loading of 30 wt% and showed a strong
relationship between the therapeutic efficacy and the size of carrier [3, 4]. Lipoplatin, a
liposomal formulation, employed electrostatic interaction to load positively charged
platinum into negatively charged 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol sodium salt
(DPPG)-lipid micelles [17, 18]. For Lipoplatin, reverse micelles were mixed with premade
liposomes and homogenized by extrusion. Drug loading of Lipoplatin was reported to be 8.9
wt%. However, these formulations were for either prodrug or charged platinum, but not for
native CDDP.
While the synthesis of CDDP (Scheme 1) is a well-documented reaction in the field of
inorganic chemistry [19], the poor solubility of CDDP in both water and organic solvents
significantly hinders the development of nanoparticulate formulations in a manner similar to
the formulation of nanoparticles with hydrophobic drugs [20, 21]. In our lab, we have
recently developed a Lipid coated Calcium Phosphate (LCP) platform to deliver diverse
bioactive molecules, such as DNA, silencing RNA and gemcitabine triphosphate [22–24].
An outer layer of a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)
(DOTAP) and high density of poly(ethylene glycol) (PEG) was coated on the calcium
phosphate cores. The cationic lipid DOTAP allows the nanoparticles to be internalized by
tumor cells more efficiently and to subsequently escape from the lysosomes. Additionally, a
high density of PEGylation will help the nanoparticles avoid reticuloendothelial system
(RES) system, improving drug pharmacokinetics and drug bioavailability. We found both
components are critical for the successful delivery of drugs into tumors.
Herein, we wish to replace calcium phosphate by CDDP as the core in order to make a
CDDP nanoparticulate formulation. Our new formulation would be favorable due to its high
drug loading capacity. Another aspect is that, our platform might be applicable to the
manufacture of many other CDDP analog nanoparticulate formulations. Our platform is
expected to improve the solubility of platinum based drug candidates with poor solubility,
such as cis-diamminedibromoplatinum(II) and cis-diamminediiodoplatinum(II). Therefore,
we hypothesize that: (1) CDDP can be encapsulated as a nanoprecipitate in a microemulsion
and stabilized in an organic solvent with 1, 2-dioleoyl-sn-glycero-3-phosphate (DOPA); (2)
DOPA-coated CDDP NPs can be further dispersed into aqueous solution by adding lipids to
form the outer leaflet of the coating bilayer; (3) the lipid bilayer-coated CDDP NPs will
show anti-cancer activity in vitro and in vivo.
2. Materials and methods
2.1. Materials
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL). Dulbecco’s Modified
Eagle Medium (DMEM), L-glutamine, penicillin Gsodium, streptomycin and fetal calf
serum were purchased from Gibco®. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[anisamide(polyethylene glycol)-2000] (DSPE-PEG-AA) was synthesized in our laboratory
as previously reported [25]. 1-Hexanol was purchased from Alfa Aesar. Igepal® CO-520,
triton™ X-100, cyclohexane, cisplatin and silver nitrate were obtained from Sigma-Aldrich
(St Louis, MO) without further purification.
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1205Lu cells were cultured in DMEM medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 20 mM of L-glutamine, 100 U/mL of penicillin G sodium, and
100 mg/mL of streptomycin at 37 °C in an atmosphere of 5% CO2 and 95% air.
2.3. Synthesis of cis-[Pt(NH3)2(H2O)2](NO3)2 precursor
To a suspension of CDDP (60 mg, 0.20 mmol) in 1.0 mL water, AgNO3 (66.2 mg, 0.39
mmol) was added. The mixture was heated at 60 °C for 3 h and then stirred overnight in a
flask protected from light with aluminum foil. Afterwards, the mixture was centrifuged at
16,000 rpm for 15 min to remove the AgCl precipitate. The solution was then filtered using
a 0.2 μm syringe filter. The concentration of cis-[Pt(NH3)2(H2O)2](NO3)2 was measured
using inductively coupled plasma mass spectrometry (ICP-MS) and adjusted to 200 mM.
2.4. Preparation of LPC NPs
The synthesis route of LPC NPs is described in Scheme 2. First, 100 μL of 200 mM cis-
[Pt(NH3)2(H2O)2](NO3)2 was dispersed in a solution composed of mixture of cyclohexane/
Igepal CO-520 (71:29, V:V) and cyclohexane/triton-X100/hexanol (75:15:10, V:V:V) to
form a well-dispersed, water-in-oil reverse micro-emulsion. Another emulsion containing
KCl was prepared by adding 100 μL of 800 mM KCl in water into a separate 8.0 mL oil
phase. One hundred μL of DOPA (20 mM) was added to the CDDP precursor phase and the
mixture was stirred. Twenty minutes later, the two emulsions were mixed and the reaction
proceeded for another 30 min. After that, 16.0 mL of ethanol was added to the micro-
emulsion and the mixture was centrifuged at 12,000 g for at least 15 min to remove the
cyclohexane and surfactants. After being extensively washed with ethanol 2–3 times, the
pellets were re-dispersed in 3.0 mL of chloroform and stored in a glass vial for further
modification.
To prepare the final NPs, 1.0 mL of LPC NPs core, 100 μL of 20 mM DOTAP/Cholesterol
(molar ratio 1:1) and 50 μL of 10 mM DSPE–PEG-2000 or DSPE–PEG–AA were
combined. After evaporating the chloroform, the residual lipids were dispersed in 1.0 mL of
d-H2O.
2.5. Characterization of NPs
The zeta potential and particle size of LPC NPs were determined using a Malvern ZetaSizer
Nano series (Westborough, MA). Transmission electron microscopy (TEM) images were
acquired using a JEOL 100CX II TEM (JEOL, Japan). The LPC NPs were negatively
stained with 2% uranyl acetate.
The drug-loading capacity and platinum content were measured using Varian 820-MS (Palo
Alto, CA). Samples were digested in 70% HNO3 and diluted in water to a final acid content
of 2%. Platinum concentration was determined using the 195Pt isotope.
The composition of DOPA-coated CDDP NPs was studied using X-ray photoelectron
spectroscopy (XPS) (Kratos Axis Ultra DLD X-ray Photoelectron Spectrometer) and NMR
(Varain Inova 400 NMR Spectrometer).
2.6. Cell toxicity assay
1205Lu cells were seeded in 96-well plates at a density of 2000 cells/well and incubated in
10% FBS of DMEM containing 100 U/mL penicillin, and 100 mg/mL streptomycin for 20
h. Then, the medium was removed and replaced by Opti-MEM containing CDDP or LPC
NPs. Forty-eight hours later, a CellTiter 96 AQueous One Solution Cell Proliferation Assay
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(Promega, Madison, WI) kit containing the tetrazolium compound MTS was used to assay
cell viability according to the manufacturer’s protocols.
2.7. Cellular uptake
1205Lu cells (2 × 105) were seeded in 35 mm MatTek glass bottom dishes (MatTek
Corporation, MA) 20 h before experiments. The cells were treated with NBD-PE labeled
LPC NPs at a concentration of 100 μM platinum (Pt) at 37 °C for 4 h. The cells were
subsequently washed twice with PBS. The nucleus was stained with Hoechest 33342
(Sigma, St Louis, MO), and lysosomes were stained by lysotracker red (Invitrogen,
Carlsbad, CA). Then, the sample was observed by Olympus FV 1000-MPE microscope
(Olympus, Japan).
To measure the amount of Pt in cells, cells were washed and lysed in order to determine
their uptake of NPs. Samples were digested in 70% HNO3 and diluted in water to a final
acid content of 2%.
2.8. In vivo anticancer efficacy evaluation
Animals were maintained in the Center for Experimental Animals (an AAALAC accredited
experimental animal facility) at the University of North Carolina. All procedures involving
experimental animals were performed in accordance with the protocols approved by the
University of North Carolina Institutional Animal Care and Use committee and conformed
to the Guide for the Care and Use of Laboratory Animals (NIH publication No. 86–23,
revised 1985). Female athymic nude mice, 5–6 weeks old and weighing 18–22 g, were
supplied by the University of North Carolina animal facility. 1205Lu xenograft tumors were
developed through subcutaneous injection of approximately 5 million 1205Lu cells in
female nude mice. 2.0 mg/kg of Pt was administered weekly by IV injection for CDDP and
LPC NPs groups. Tumor growth and body weight were monitored. Tumor volume was
calculated using the following formula: , with W being smaller than L.
Finally, mice were sacrificed by CO2 inhalation. Tumors were collected after treatment and
were formalin fixed and processed for TUNEL assay.
2.9. TUNEL assay
The tumors were fixed in 4.0% paraformaldehyde (PFA) and subsequently paraffin-
embedded, to be sectioned at the UNC Lineberger Comprehensive Cancer Center Animal
Histopathology Facility. To detect apoptotic cells in tumor tissues, a terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, using a DeadEndTM
Fluorometric TUNEL System (Promega, Madison, WI), was performed, following the
manufacturer’s protocol. Cell nuclei, which were stained with green fluorescence, were
defined as TUNEL-positive nuclei. TUNEL-positive nuclei were monitored using a
fluorescence microscope (Nikon, Tokyo, Japan). The cell nuclei were stained with 4, 6-
diaminidino-2-phenyl-indole (DAPI) (Vectashield, Vector Laboratories, Inc., Burlingame,
CA). To quantify TUNEL-positive cells, green-fluorescence-positive cells were counted in
three images taken at 40× magnification.
2.10. Statistical analysis
Quantitative data were expressed as mean ± SEM. The analysis of variance is completed
using a one-way ANOVA. P < 0.05 was considered statistically significant.
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3. Results and discussions
3.1. Synthesis and characterization of DOPA-coated CDDP Cores
CDDP NPs were synthesized in microemulsion during the reaction between KCl and its
highly soluble cis-[Pt(NH3)2(H2O)2](NO3)2 precursor. To synthesize stable CDDP
precipitates, DOPA, which is known to strongly interact with the platinum cation at the
interface [26–28], was used. To maximize the yield of CDDP NPs, an excess of KCl was
used to inhibit hydrolysis equilibrium. After CDDP was precipitated, CDDP cores were then
coated with a hydrophobic layer of DOPA (Scheme 2). DOPA-coated CDDP NPs were
purified in a manner similar to that of silica NPs, which are also synthesized in
microemulsion. Ethanol was added to destroy the emulsion and precipitate CDDP NPs.
DOPA-coated CDDP NPs precipitate was then collected by centrifugation and readily
dispersed in chloroform, toluene or hexane. By adjusting the composition of the surfactant
system, the size of the NPs can be altered between 12 to 75 nm in diameter (Fig. 1).
X-ray photoelectron spectroscopy (XPS) was used to confirm the composition of DOPA-
coated CDDP NPs (Fig. 2). The ratio of N:Pt:Cl was 2:1:1.8, and a small amount of
phosphorous element was also present, as expected from the presence of DOPA (Fig. 2D).
In addition, no potassium element was found. We also confirmed the composition of DOPA-
coated CDDP NPs using 1H NMR spectra in DMF-d7 (shown in Fig. 3). The data illustrated
that the major peaks of DOPA-coated NPs were consistent with those of CDDP; and
therefore, we can conclude that NPs are core-shell structures with CDDP as the core and
DOPA as a coating layer. The DOPA-coated CDDP NPs were expected to have high drug
loading capacity. We used ICP-MS to measure the content of Pt and used NBD-labeled
DOPA to measure the amount of DOPA on the surface of CDDP NPs. The results indicated
that the yield of DOPA-coated CDDP NPs was approximately 45 ± 3 wt%. The NPs were
also characterized with drug loading capacity as high as 93 ± 2 wt%.
3.2. Facile surface engineering of hydrophobic DOPA-coated CDDP NPs with outer leaflet
lipids
To further disperse the hydrophobic DOPA-coated CDDP NPs into aqueous solution,
additional lipids composed of DOTAP, cholesterol, DSPE-mPEG and DSPE-PEG-AA
(molar ratio 4: 4: 1: 1) were used. These lipids self-assembled in water into the outer leaflet
of the bilayer through a hydrophobic interaction with DOPA-coated CDDP NPs as a
template [29, 30]. The DOPA layer served as inner leaflet of the asymmetrical bilayer
coating CDDP core. Composition of outer leaflet lipids was carefully chosen to contain
steric lipid (DSPE-mPEG) for prolonged circulation of NPs in the blood stream [31], DSPE-
PEG-anisamide for vivid uptake of NPs by the tumor cells and DOTAP for rupturing
endosomes [32, 33].
The final NPs are named Lipid-Pt-Cl (LPC) NPs. LPC NPs were then purified via
centrifugation to remove free liposomes formed as the result of excess outer leaflet lipids.
LPC NPs were negatively stained with uranyl acetate and examined using TEM (Fig. 4A).
The clear core/membrane structure revealed the bilayer coating the surface of LPC NPs. As
shown in Fig. 4A, size of the particles determined using TEM was approximately 15 nm,
which was smaller than the results obtained from dynamic light scattering (DLS) (Fig. 4B).
Zeta potential of the NPs was +15 ± 0.3 mV and DLS results showed that distribution of
LPC NPs was narrow, with a PDI of 0.15 ± 0.02. The drug loading of LPC NPs was
approximately 82 ± 5 wt%. Overall, these results indicate LPC NPs are well dispersed in
aqueous solution and characterized by a high drug loading.
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Previously, a similar formulation, Lipoplatin, employs electrostatic interaction to load
positively charged platinum into negatively charged DPPG-lipid micelles. Reverse micelles
were mixed with premade liposomes and homogenized by extrusion [18]. Drug loading was
reported to be inefficient, yielding a loading of 8.9 wt% cisplatin [17]. In contrast, LPC NPs
employed a microemulsion system to synthesize a hydrophobic, pure cisplatin-based
nanoparticle with tunable size for customized delivery, which further surface-functionalized
with amphiphilic lipids to ensure successful evasion of reticuloendothelial system and
efficient tumor targeting. LPC NPs achieved high loading capacity due to the solid,
cisplatin-based core, producing nanoparticles containing up to 80 wt% drug. In addition,
DOPA-coated CDDP NPs was prepared with the hydrophobic surface in organic solvent,
allowing versatile coating and surface modification for a variety of purposes, in a manner
similar to quantum dots and iron nanoparticles. We believe our platform may be of
significant value to the research community as an alternative approach to develop
nanoparticles made of the drug itself rather than loaded with drug as cargos.
3.3. Cell toxicity and cellular uptake of LPC NPs in 1205Lu cells
To test the anticancer efficacy of LPC NPs, we evaluated the performance of LPC NPs in
1205Lu melanoma cancer cells. DOPA-coated CDDP NPs with size of 12 nm were used to
prepare LPC NPs for the evaluation of anti-cancer effect. As shown in Fig. 5A, the IC50 of
CDDP and LPC NPs in 1205Lu cells was 12.4 ± 1.5 μM and 0.80 ± 0.2 μM respectively.
Additionally, the empty liposome vesicles having a composition similar to that of the
coating bilayer of LPC did not show any cytotoxicity (data not shown). The cellular uptake
of LPC NPs was studied using confocal microscopy and ICP-MS. We labeled LPC NPs
using fluorescent 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-
benzoxadiazol-4-yl) (ammonium salt) (NBD-PE) lipid and incubated them with cells. Some
of the LPC NPs were co-localized with lysosomes as shown by the yellow areas (Fig. 6).
However, while a large number of NPs were endocytosed, they showed little accumulation
in the lysosomes; a phenomenon that is facilitated by the capability of DOTAP to enhance
endosome escape. Quantitative data indicated that cellular uptake of LCP NPs was more
efficient than free CDDP (Fig. 5B). LPC NPs delivering CDDP showed 11-fold increase in
drug internalization over free CDDP, which explained the low IC50 of LPC NPs.
3.4. In vivo anti-cancer efficacy of LPC NPs on 1205Lu xenograft tumor and TUNEL assay
Efficacy of LPC NPs in a xenograft tumor model was further evaluated. Fig. 7A illustrates
that free CDDP only had a partial effect on tumor growth inhibition at the dose and dose
schedule adopted in the experiment. In contrast, tumor growth was significantly suppressed
when LPC NPs were administered intravenously. In addition, mice in the treatment groups
did not exhibit significant weight loss (Fig. 7B). Terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay is a method for detecting DNA fragmentation
occurring in apoptosis by labeling the terminal end of nucleic acids. TUNEL images (Fig.
7C) indicate that LPC NPs induced noticeably more apoptosis (32.1 ± 3.6%) than free
CDDP (6.3 ± 0.8%), which is consistent with the observed efficacy of tumor inhibition. All
in all, our data suggest that LPC NPs are both effective and safe in treating 1205Lu
melanoma tumors. Biodistribution and lack of nephro- and hepato-toxicities of LPC NPs
have been studied and published elsewhere [34].
4. Conclusions
Successful fabricated CDDP NPs are characterized with high drug loading capacity and
optimal aqueous dispensability. Engineered via the microemulsion method and coated with
DOPA and additional outer leaflet layers, LPC NPs exhibited significant antitumor effects
both in vitro and in vivo. By adjusting the fabrication parameters, size of CDDP NPs can
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also be altered between 12–75 nm for optimal tumor accumulation. Note that CDDP is the
major ingredient of LPC. As far as we know, this is a good example of using an unmodified
drug as a material for the assembly of NPs. Synthesis of LPC NPs can be applied to
formulate other insoluble drugs.
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TEM images of DOPA-coated, CDDP NPs prepared using different surfactant systems. The
surfactants used to create the microemulsion were a mixture of Igepal-520 system
(Igepal-520: cyclohexane=30:70 (v/v)) and Triton X-100 system (Triton X-100: Hexanol:
cyclohexane=15:10:75 (v/v/v); the volume ratio of Igepal-520 system to Triton X-100
system was 6:2 (A), 2:6 (B) and 0:8 (C) respectively.
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XPS study of Pt 4f (A), N 1s (B), Cl 2p (C) and P 2p (D) on CDDP and DOPA-coated
CDDP NPs.
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1H NMR spectra of CDDP and DOPA-coated CDDP NPs in DMF-d7.
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TEM image of CDDP NPs negatively stained using uranyl acetate (A) and size distribution
by DLS (B) of LPC NPs.
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Cytotoxicity of free CDDP and LPC NPs in 1205Lu cells (A) and the amount of cell uptake
of CDDP and LPC NPs in 1205Lu tumor cells quantified using ICP-MS (B). Data is
expressed as the amount of the Pt drug associated with cells incubated with 100 μM CDDP
or LPC NPs in 24 well plates. Each bar represents the mean ± SEM of three independent
experiments. The analysis of variance was completed using a one-way ANOVA.
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Cell uptake of LPC NPs in 1205Lu cell line imaged by confocal microscopy. The LPC NPs
were labeled with NBD-PE lipid (green). Lysosome (red) and nucleus (blue) were stained by
Lysotracker-Red and Hoechst 33342, separately.
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Effects of free CDDP and LPC NPs on growth of 1205Lu tumors (A) and relative body
weight (B). Free CDDP and LPC NPs were administered intravenously at a dose of 2.0 mg/
kg Pt. After mice were sacrificed, tumor tissue was sectioned for TUNEL assay (C). The
arrowheads indicate the time of injection. Tumor volume (TV) was calculated using the
following formula: , with W < L. The results are shown as means ± SEM
(error bars) of 5 animals per group and are representative of two independent experiments.
The analysis of variance is completed using a one-way ANOVA. *, P < 0.05; **, P < 0.01.
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Classic synthesis route of CDDP.
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Synthesis of lipid bilayer-coated CDDP NPs using a reverse microemulsion method.
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